Protagonist Therapeutics (PTGX) Key Ratios
$146.49
As on 01-Sep-2026 16:00EDT
Market cap
$9,339 Mln
Revenue (TTM)
$282 Mln
P/E Ratio
140.1
P/B Ratio
11.5
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | 278.72 | 3,749.17 | 34.81 | 20.07 | 59.62 |
| EBIT | -- | -- | -250.20 | 12.02 | 0.17 |
| Net Profit | 4,204.76 | 568.35 | 59.32 | 37.55 | 24.72 |
| EPS | 4,173.59 | 518.91 | 44.83 | 33.62 | 20.49 |
| Book Value | -- | -- | -4.91 | 30.24 | 6.49 |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Dec-25 | Dec-24 |
| EBIT-Margin
| -116.10 | -260.29 | -28.64 | -281.01 | 64.32 |
| Net Margin
| -- | -428.94 | 29.40 | -- | -- |
| Return on equity
| 1.87 | -17.11 | 11.39 | -20.18 | 54.39 |
| Return on Capital
| 1.85 | -16.78 | -- | -19.85 | 53.75 |
| Return on Assets
| 1.82 | -14.67 | 9.89 | -18.40 | 49.91 |
| Debt to Equity (x)
| -- | -- | 0.00 | 0.02 | 0.02 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Protagonist Therapeutics (PTGX)
|
--
|
-19.85
|
53.75
|
-28.35
|
-47.00
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
11.39
Higher than Peers by 51.79
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Protagonist Therapeutics (PTGX)
|
11.39
|
-20.18
|
54.39
|
-28.59
|
-47.87
|
|
Peer Median
|
-40.40
|
--
|
--
|
--
|
--
|
ROA
9.89
Higher than Peers by 40.87
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Protagonist Therapeutics (PTGX)
|
9.89
|
-18.40
|
49.91
|
-26.06
|
-41.44
|
|
Peer Median
|
-30.98
|
--
|
--
|
--
|
--
|
EBIT Margin
-28.64
Higher than Peers by 54.97
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Protagonist Therapeutics (PTGX)
|
-28.64
|
-281.01
|
64.32
|
-131.59
|
-494.24
|
|
Peer Median
|
-83.62
|
--
|
--
|
--
|
--
|
Net Margin
29.40
Higher than Peers by 122.07
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Protagonist Therapeutics (PTGX)
|
29.40
|
-282.83
|
63.34
|
-131.59
|
-403.83
|
|
Peer Median
|
-92.67
|
--
|
--
|
--
|
--
|
Cash Profit Margin
0.00
Higher than Peers by 0.00
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Protagonist Therapeutics (PTGX)
|
0.00
|
--
|
--
|
--
|
--
|
|
Peer Median
|
0.00
|
--
|
--
|
--
|
--
|
Revenue Growth
34.81
Lower than Peers by 19.15
Year on year growth in net sales
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Protagonist Therapeutics (PTGX)
|
34.81
|
-0.89
|
6.24
|
1.26
|
-0.03
|
|
Peer Median
|
53.95
|
--
|
--
|
--
|
--
|
EBIT Growth
-250.20
Lower than Peers by 249.40
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Protagonist Therapeutics (PTGX)
|
-250.20
|
-146.28
|
453.88
|
39.90
|
-4.64
|
|
Peer Median
|
-0.80
|
--
|
--
|
--
|
--
|
Net Profit Growth
59.32
Higher than Peers by 66.62
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Protagonist Therapeutics (PTGX)
|
59.32
|
-147.29
|
448.54
|
36.02
|
1.70
|
|
Peer Median
|
-7.30
|
--
|
--
|
--
|
--
|
EPS Growth
44.83
Higher than Peers by 30.18
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Protagonist Therapeutics (PTGX)
|
44.83
|
-1.49
|
4.24
|
0.49
|
0.04
|
|
Peer Median
|
14.65
|
--
|
--
|
--
|
--
|
Book Value Growth
12.68
Higher than Peers by 22.85
Year on year growth in book value per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Protagonist Therapeutics (PTGX)
|
12.68
|
--
|
--
|
--
|
--
|
|
Peer Median
|
-10.18
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
--
--
Total debt / Net worth
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Protagonist Therapeutics (PTGX)
|
--
|
0.02
|
0.02
|
0.00
|
0.02
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
0.00
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Protagonist Therapeutics (PTGX)
|
0.00
|
0.00
|
0.00
|
0.00
|
0.01
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
21.71
Higher than Peers by 15.90
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Protagonist Therapeutics (PTGX)
|
21.71
|
12.71
|
12.48
|
16.71
|
7.80
|
|
Peer Median
|
5.81
|
--
|
--
|
--
|
--
|
Quick Ratio
21.71
Higher than Peers by 16.01
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Protagonist Therapeutics (PTGX)
|
21.71
|
--
|
--
|
17.20
|
7.80
|
|
Peer Median
|
5.70
|
--
|
--
|
--
|
--
|
Interest Coverage
--
--
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Protagonist Therapeutics (PTGX)
|
--
|
--
|
--
|
--
|
-38.99
|
|
Peer Median
|
-2.09
|
--
|
--
|
--
|
--
|
Operating Efficiency
Debtors to sales
4.76
Lower than Peers by 14.38
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Protagonist Therapeutics (PTGX)
|
4.76
|
9.77
|
38.78
|
17.22
|
0.20
|
|
Peer Median
|
19.14
|
--
|
--
|
--
|
--
|
Asset Turnover
0.34
Higher than Peers by 0.27
Sales / Average Total Assets
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Protagonist Therapeutics (PTGX)
|
0.34
|
0.07
|
0.79
|
0.20
|
0.09
|
|
Peer Median
|
0.06
|
--
|
--
|
--
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Protagonist Therapeutics (PTGX)
|
--
|
686.53
|
75.17
|
31.61
|
37.00
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Protagonist Therapeutics (PTGX)
|
--
|
--
|
-1,273.63
|
-574.89
|
1,488.08
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Protagonist Therapeutics (PTGX)
|
--
|
1,036.71
|
147.12
|
243.28
|
927.28
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Protagonist Therapeutics (PTGX)
|
--
|
--
|
-1,345.58
|
-786.57
|
597.79
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
140.13
--
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Protagonist Therapeutics (PTGX)
|
140.13
|
-42.66
|
9.31
|
-17.95
|
-4.35
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Price / Book Value
11.49
Higher than Peers by 6.31
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Protagonist Therapeutics (PTGX)
|
11.49
|
9.03
|
3.80
|
4.21
|
2.49
|
|
Peer Median
|
5.18
|
--
|
--
|
--
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Protagonist Therapeutics (PTGX)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EV/EBITDA
148.58
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Protagonist Therapeutics (PTGX)
|
148.58
|
-39.00
|
7.69
|
-14.23
|
-2.37
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Market Cap
9,339
Higher than Peers by 9,193
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Protagonist Therapeutics (PTGX)
|
9,339
|
--
|
--
|
--
|
--
|
|
Peer Median
|
146
|
--
|
--
|
--
|
--
|